FY25 consensus $7.32. Raises FY25 revenue view to $854M-$873M from $818M-$834M, consensus $847.99M. Raises FY25 adjusted EBITDA view to $221M-$228M from $213M-$223M.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals reports Q3 adjusted EPS $2.04, consensus $1.77
- ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ANI Pharmaceuticals price target raised to $90 from $77 at Truist
- ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares
- Strong Growth Potential for ANI Pharmaceuticals Driven by Cortrophin Gel and Strategic Expansion